Regeneron director sells 1,638 shares after option

REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported option exercises and related share sales.

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported option exercises and related share sales. On February 19, 2026, Zoghbi exercised a non-qualified stock option for 1,638 shares at an exercise price of $0.00, receiving 1,638 shares of common stock at $376.69 per share.

The same day, Zoghbi executed multiple open-market sales totaling 1,638 common shares at prices generally in the high-$770s to around $790 per share, pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025. After these transactions, Zoghbi held 1,703 Regeneron common shares directly.

Insider Trade Summary

Exercise and Sale: 1,638 shares ($663K approx. pre-tax spread)

Exercise and Sale 13 txns

Insider Zoghbi Huda Y

Role Director

Sold 1,638 shs ($1.28M)

Approx. gross sale proceeds $1.28M

Approx. exercise cost $617K

Approx. pre-tax spread $663K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	1,638	$0.00	$0.00
Exercise	Common Stock	1,638	$376.69	$617K
Sale	Common Stock	49	$774.68	$38K
Sale	Common Stock	50	$775.50	$39K
Sale	Common Stock	53	$778.47	$41K
Sale	Common Stock	208	$779.55	$162K
Sale	Common Stock	331	$780.45	$258K
Sale	Common Stock	209	$781.28	$163K
Sale	Common Stock	298	$782.10	$233K
Sale	Common Stock	220	$783.29	$172K
Sale	Common Stock	160	$784.45	$126K
Sale	Common Stock	56	$785.61	$44K
Sale	Common Stock	4	$790.00	$3K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 800 contracts (Direct); Common Stock — 1,703 shares (Direct)

Footnotes (10)

1. F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
2. F2. Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
3. F3. Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
4. F4. Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
5. F5. Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
6. F6. Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
7. F7. Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
8. F8. Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
9. F9. Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.
10. F10. The stock option vested in three equal annual installments, commencing one year after the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did REGN director Huda Y. Zoghbi report on February 19, 2026?

Huda Y. Zoghbi reported exercising a non-qualified stock option for 1,638 shares, then selling 1,638 Regeneron common shares in multiple open-market trades. These transactions left her with 1,703 shares of REGN common stock held directly afterward.

How many Regeneron (REGN) shares did the director sell, and at what prices?

The director sold 1,638 REGN common shares in several open-market transactions. Reported per-share prices were generally in the high-$770s to around $790, with specific volume-weighted averages disclosed across narrow intraday price ranges for each sale group.

What stock option exercise did the REGN Form 4 disclose for Huda Y. Zoghbi?

The Form 4 shows Zoghbi exercised a non-qualified stock option covering 1,638 Regeneron shares at an exercise price of $0.00 per share. The underlying common stock was reported with a transaction price of $376.69 per share in connection with the derivative exercise.

Was the REGN director’s February 19, 2026 trading under a Rule 10b5-1 plan?

Yes. A footnote states the disposition and acquisition were made under a plan intended to comply with Rule 10b5-1(c), adopted on November 20, 2025. Such plans prearrange trades according to set terms, separate from day-to-day market decisions.

How many Regeneron (REGN) shares does Huda Y. Zoghbi own after these transactions?

After exercising options and selling shares, Huda Y. Zoghbi held 1,703 Regeneron common shares directly. This figure reflects the reported balance following the February 19, 2026 open-market sales totaling 1,638 shares disclosed in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zoghbi Huda Y

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		M(1)		1,638	A	$376.69	3,341	D
Common Stock	02/19/2026		S(1)		49	D	$774.68	3,292	D
Common Stock	02/19/2026		S(1)		50	D	$775.5	3,242	D
Common Stock	02/19/2026		S(1)		53	D	$778.47(2)	3,189	D
Common Stock	02/19/2026		S(1)		208	D	$779.55(3)	2,981	D
Common Stock	02/19/2026		S(1)		331	D	$780.45(4)	2,650	D
Common Stock	02/19/2026		S(1)		209	D	$781.28(5)	2,441	D
Common Stock	02/19/2026		S(1)		298	D	$782.1(6)	2,143	D
Common Stock	02/19/2026		S(1)		220	D	$783.29(7)	1,923	D
Common Stock	02/19/2026		S(1)		160	D	$784.45(8)	1,763	D
Common Stock	02/19/2026		S(1)		56	D	$785.61(9)	1,707	D
Common Stock	02/19/2026		S(1)		4	D	$790	1,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$376.69	02/19/2026		M(1)			1,638	(10)	01/03/2027	Common Stock	1,638	$0.0	800	D

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.

2. Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

8. Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

9. Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price.

10. The stock option vested in three equal annual installments, commencing one year after the date of grant.

	/s/ Huda Y. Zoghbi	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.